Skip to main content

Table 1 Clinical characteristics of the study cohort

From: Thyroid disease and cancer in kidney transplantation: a single-center analysis

 

With nodule (n=204)

Without nodule (n=556)

P

Male (%)

48%

47%

Ns

Living/Deceased

40/164

60/494

Ns

Age (years)

48 ±12.3

54 ±10.5

< 0.04

Cause of ESRD (n,%)

 Glomerulonephritis

95 (46.6)

265 (47.6)

Ns

 Polycystic Kidney Disease

40 (19.7)

87 (15.7)

Ns

 Diabetes

30 (14.7)

60 (10.8)

Ns

 Other causes

39 (19.1)

144 (25.9)

Ns

Waiting list (months)

21 ±10.4

18.2 ±16.4

Ns

Pretransplant dialysis

32 ±16.3

29 ±22.3

< 0.05

Donor age

55.6 ± 15.1

54.2 ±18.1

Ns

Immunosuppression (n, %)

 Induction

60 (29.4)

160 (28.2)

Ns

 TAC+MPA+Ster

170 (83.3)

470 (83)

Ns

 CYA+MPA+Ster

20 (9.8)

60 (10.6)

Ns

 Eve+MPA+Ster

24 (11.7)

36 (6.3)

Ns

BMI (KG/m2)

25 ±4.7

26.1 ±3.9

Ns

Serum Creatinine (mg/dL)

1.53 ±0.7

1.49 ±0.6

Ns

  1. ESRD end-stage renal disease, TAC tacrolimus, MPA mycophenolic acid, Ster steroids, CyA cyclosporine, EVE, everolimus, BMI body mass index NS, not significant